Professor Desmond Johnston and his team will work closely with researchers across the UK to increase the value of ADDRESS (the After Diabetes Diagnosis Research Support System), which helps to recruit people newly diagnosed with Type 1 diabetes and their families into trials of new immune therapies.
Background to research
New therapies to prevent or reduce the impact of Type 1 diabetes will be need to be given to people at an early stage, before all of their insulin-producing cells are destroyed. Trials of such therapies will therefore need people to take part a few months after their diagnosis with Type 1 diabetes, when they are still making some of their own insulin.
This is often a challenging time for people with Type 1 diabetes and their families and, as a result, trial recruitment is very challenging and less than 16% of eligible people are currently taking part in Type 1 vaccine trials in the UK.
ADDRESS (the After Diabetes Diagnosis Research Support System) is a database of information and biological samples from people with newly diagnosed Type 1 diabetes (and their siblings) who have agreed to be contacted about research.
ADDRESS already includes over 3,000 people and around 75 new people join every month. Fifteen research studies have already used or are currently using ADDRESS to help them involve people with Type 1 diabetes and their families.
Professor Desmond Johnston and his team will work closely with researchers on other new projects being supported by Diabetes UK, Tesco and JDRF to increase the value of ADDRESS and extend the recruitment of people newly diagnosed with Type 1 diabetes who are willing to take part in research.
As with the existing system, new ADDRESS participants will be identified through NHS research networks and their data stored in a secure database to extend the usefulness of this resource for new trials of immune therapies.
Biological samples will also be taken to allow measurement of immune markers and DNA.
Potential benefit to people with diabetes
This study will expand ADDRESS and help researchers recruit more and more people with newly diagnosed Type 1 diabetes and their families into trials of new immune therapies.
This involvement will be vitally important for the trials that will pioneer new immune therapies to reduce the impact of Type 1 diabetes in those who already have it, and to prevent the condition in those at high risk.